Approvals of drugs with uncertain benefit-risk profiles in Europe

European Journal of Internal Medicine
Rita BanziSilvio Garattini

Abstract

This paper examines conditional approvals that allow the marketing of medicines with unsettled benefit-risk profiles in the European Union. We identified medicines that had received conditional approval from the European Medicines Agency in the period January 2006-June 2015. We searched the reasons and bases for approvals, the median time to address the specific obligations imposed in order to cover the information gap and allow regular authorisations, and their extent of fulfilment. Of the 26 products conditionally authorised two were withdrawn for commercial reasons, ten were switched to regular approval, and 14 are still under conditional approval. Conditional approval was granted mainly to medicinal products intended for seriously debilitating disease or life-threatening disease. The median time to address the specific obligations was four years (range 0.2 to 7.7). There were delays or discrepancies in the fulfilment of these obligations in more than one third of the authorisation procedures. In most cases there was limited evidence supporting the positive benefit-risk balance at the time of approval. Delays or discrepancies in the fulfilment of obligations allow medicinal products with unsettled benefit-risk profiles onto ...Continue Reading

References

Aug 3, 2002·BMJ : British Medical Journal·Silvio Garattini, Vittorio Bertele
Nov 30, 2002·BMJ : British Medical Journal·Hilary CalvertAdrian L Harris
Dec 15, 2006·British Journal of Clinical Pharmacology·Johan C F van LuijnHubert G M Leufkens
Apr 7, 2007·AIDS·Richard HaubrichUNKNOWN POWER 2 Study Group
May 29, 2007·European Journal of Clinical Pharmacology·Vittorio Bertele'Silvio Garattini
Sep 12, 2007·Pharmaceutical Statistics·Kevin CarrollAlan Phillips
Mar 5, 2008·The British Journal of Surgery·UNKNOWN European Union Network of Excellence (EUNE) for Gastric Cancer Steering Group
Sep 13, 2008·Nature Reviews. Drug Discovery·Hans-Georg EichlerAlasdair Breckenridge
Oct 25, 2008·Nature Reviews. Drug Discovery·Janice M ReichertBodi D Zhang
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food and Drug Administration
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alberto Sobrero, Paolo Bruzzi
Oct 28, 2010·JAMA : the Journal of the American Medical Association·Mike Mitka
Mar 23, 2011·Journal of the National Cancer Institute·John R JohnsonRichard Pazdur
Apr 20, 2011·British Journal of Clinical Pharmacology·Arna H ArnardottirPeter G M Mol
Dec 14, 2011·Nature Biotechnology·Jeffrey L Fox
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Jul 16, 2013·Epilepsia·Elaine C WirrellMarcio Sotero de Menezes
Oct 22, 2013·PLoS Medicine·Corrado Barbui, Irene Bighelli
Mar 29, 2014·The New England Journal of Medicine·Jonathan J DarrowAaron S Kesselheim
Jun 26, 2014·The New England Journal of Medicine·Aaron S Kesselheim, Jonathan J Darrow
Aug 13, 2014·Therapeutics and Clinical Risk Management·Eric LeibertWilliam N Rom
Sep 23, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Linus JönssonMichael Drummond
Mar 31, 2015·BMJ : British Medical Journal·Gregg Gonsalves, Diana Zuckerman

❮ Previous
Next ❯

Citations

Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MartinalboF Pignatti
Mar 19, 2016·British Journal of Clinical Pharmacology·Jarno HoekmanMarie L De Bruin
Oct 14, 2016·Frontiers in Pharmacology·Michael ErmischBrian Godman
Jun 27, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N GrössmannC Wild
Dec 16, 2017·European Journal of Clinical Investigation·Peter C Gøtzsche
Aug 24, 2018·Drug and Therapeutics Bulletin
Aug 3, 2018·International Journal of Clinical Pharmacy·Paolo BaldoSara Francescon
Feb 7, 2019·Wiener medizinische Wochenschrift·Nicole GrössmannClaudia Wild
Oct 28, 2018·Applied Health Economics and Health Policy·Dominik J Wettstein, Stefan Boes
May 18, 2019·American Society of Clinical Oncology Educational Book·Bishal GyawaliAriadna Tibau
Nov 7, 2019·Applied Health Economics and Health Policy·Caridad PontesBrian Godman
Apr 27, 2018·Neurology·Chiara GerardiRita Banzi
Mar 9, 2017·BMC Medicine·Mark S CorbettNerys Woolacott
Sep 8, 2017·Frontiers in Pharmacology·Patricia Vella BonannoAlan Haycox
Jun 27, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·J LiI Durand-Zaleski
Nov 2, 2019·Health Economics, Policy, and Law·Jessica PaceWendy Lipworth
Jul 9, 2020·International Journal of Technology Assessment in Health Care·Pilar Pinilla-DominguezElias Mossialos
Jul 23, 2020·Cadernos de saúde pública·Vera Lúcia Edais Pepe, Hillegonda Maria Dutilh Novaes
Apr 11, 2018·Frontiers in Pharmacology·Jacoline C BouvySarah Garner
Nov 29, 2017·European Journal of Clinical Pharmacology·Silvio Garattini, Vittorio Bertele'
Jul 16, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Patricia McGettiganPeter G M Mol
Nov 21, 2017·Biomedicine Hub·Denis Horgan
Mar 13, 2021·Journal of Community Genetics·Christian Munthe
Aug 29, 2016·JACC. Basic to Translational Science·Gail A Van Norman
May 2, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sasha ThomsonKelvin K W Chan
Oct 19, 2021·The Lancet Regional Health. Europe·Marco CavaleriMelanie Carr

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.